{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:21Z","timestamp":1791920061749,"version":"4.3.4"},"reference-count":186,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,19]],"date-time":"2020-01-19T00:00:00Z","timestamp":1579392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>With the incidence of sleeping sickness in decline and genuine progress being made towards the WHO goal of eliminating sleeping sickness as a major public health concern, this is a good moment to evaluate the drugs that \u2018got the job done\u2019: their development, their limitations and the resistance that the parasites developed against them. This retrospective looks back on the remarkable story of chemotherapy against trypanosomiasis, a story that goes back to the very origins and conception of chemotherapy in the first years of the 20 century and is still not finished today.<\/jats:p>","DOI":"10.3390\/tropicalmed5010014","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T04:27:09Z","timestamp":1579494429000},"page":"14","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-1827","authenticated-orcid":false,"given":"Harry","family":"P. De Koning","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1358\/dot.2019.55.11.3068795","article-title":"Fexinidazole for the treatment of human African trypanosomiasis","volume":"55","author":"Fairlamb","year":"2019","journal-title":"Drugs Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1586\/14787210.2014.959496","article-title":"Treatment options for second-stage gambiense human African trypanosomiasis","volume":"12","author":"Eperon","year":"2014","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_3","unstructured":"(2019, December 15). R&D Portfolio Update February 2019: DNDi Sleeping Sickness Programme. Available online: www.dndi.org\/2019\/media-centre\/news-views-stories\/news\/sleepingsickness_rnd_status_2019\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jacobs, R.T., Nare, B., Wring, S.A., Orr, M.D., Chen, D., Sligar, J.M., Jenks, M.X., Noe, R.A., Bowling, T.S., and Mercer, L.T. (2011). SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001151"},{"key":"ref_5","first-page":"656","article-title":"Mort par hypoglyc\u00e9mie dans les trypanosomiases aigu\u00ebs","volume":"99","author":"Dubois","year":"1928","journal-title":"CR Soc. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/infdis\/159.2.360","article-title":"Severe African trypanosomiasis with spurious hypoglycemia","volume":"159","author":"Nieman","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_7","unstructured":"Mulligan, H.W. (1970). Review of chemotherapeutic and chemoprophylactic drugs. The African Trypanosomiases, George Allen\/Unwin Ltd."},{"key":"ref_8","first-page":"21","article-title":"Zur glykopriven Therapie und Prophylaxe mit sowohl toxische als auch atoxische wirkende Substanzen bei der experimentellen Trypanosomen-und Treponemen-Infektion","volume":"89","author":"Schern","year":"1936","journal-title":"Z Immun. Exp. Ther."},{"key":"ref_9","first-page":"1","article-title":"Chemotherapeutische Wirkung und Kohlehydratstoffwechsel: Die Heilwirkung von Guanidinderivaten auf die Trypanosomeninfektion","volume":"86","year":"1935","journal-title":"Z Immun. Exp. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0140-6736(00)88968-0","article-title":"New trypanocidal substances","volume":"223","author":"King","year":"1937","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/00034983.1937.11684999","article-title":"Studies in Chemotherapy XVI: The trypanocidal action of synthalin","volume":"31","author":"Lourie","year":"1937","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00034983.1939.11685073","article-title":"Studies in Chemotherapy XVI: The trypanocidal action of certain aromatic diamidines","volume":"33","author":"Lourie","year":"1939","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_13","first-page":"71","article-title":"A peculiar neurological sequel to administration of 4:400-diamidino-diphenyl-ethylene (M&B 744)","volume":"77","author":"Napier","year":"1942","journal-title":"Indian Med. Gaz."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4269\/ajtmh.1949.s1-29.173","article-title":"MelB in the treatment of human trypanosomiasis","volume":"29","author":"Friedheim","year":"1949","journal-title":"Am. J. Trop. Med."},{"key":"ref_15","first-page":"277","article-title":"Summary of cases of human early trypanosomiasis treated with Berenil at EATRO","volume":"69","author":"Temu","year":"1975","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_16","first-page":"7219","article-title":"Distribution of furamidine analogues in tumor cells: Targeting of the nucleus or mitochondria depending on the amidine substitution","volume":"62","author":"Lansiaux","year":"2002","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1128\/AAC.00005-07","article-title":"Diphenyl furans and aza analogs: Effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes","volume":"51","author":"Mathis","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13680","DOI":"10.1021\/ja027953c","article-title":"Strong binding in the DNA minor groove by an aromatic diamidine with a shape that does not match the curvature of the groove","volume":"124","author":"Nguyen","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.biochi.2008.02.017","article-title":"Antiparasitic compounds that target DNA","volume":"90","author":"Wilson","year":"2008","journal-title":"Biochimie"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liu, L., Wang, F., Tong, Y., Li, L.-F., Liu, Y., and Gao, W.-Q. (2019). Pentamidine inhibits prostate cancer progression via selectively inducing mitochondrial DNA depletion and dysfunction. Cell Prolif., e12718.","DOI":"10.1111\/cpr.12718"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(05)66793-1","article-title":"Detection of arsenical drug resistance in Trypanosoma brucei using a simple fluorescence test","volume":"366","author":"Stewart","year":"2005","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1550-7408.1976.tb03787.x","article-title":"Pentamidine transport and sensitivity in brucei-group trypanosomes","volume":"23","author":"Damper","year":"1976","journal-title":"J Protozool"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-2952(76)90213-6","article-title":"Pentamidine transport in Trypanosoma brucei\u2014Kinetics and specificity","volume":"25","author":"Damper","year":"1976","journal-title":"Biochem. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.00192-06","article-title":"Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes","volume":"50","author":"Mathis","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Eze, A.A., Gould, M.K., Munday, J.C., Tagoe, D.N.A., Stelmanis, V., Schnaufer, A., and De Koning, H.P. (2016). Loss of mitochondrial membrane potential is a late adaptation of Trypanosoma brucei brucei to isometamidium preceded by mutations in the \u03b3 subunit of the F1F0-ATPase. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004791"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/jac\/dkq401","article-title":"Symmetrical choline-derived dications display strong anti-kinetoplastid activity","volume":"66","author":"Ibrahim","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.01551-10","article-title":"Trypanocidal furamidine analogues: Influence of pyridine nitrogens on trypanocidal activity, transport kinetics and resistance patterns","volume":"55","author":"Ward","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.00642-07","article-title":"The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei","volume":"52","author":"Lanteri","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpddr.2015.12.002","article-title":"Trypanocidal action of bisphosphonium salts through a mitochondrial target in bloodstream form Trypanosoma brucei","volume":"6","author":"Alkhaldi","year":"2016","journal-title":"Int. J. Parasitol. Drugs Drug. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/med.21560","article-title":"Alternative Oxidase inhibitors: Development and efficient mitochondrion-targeting as a strategy for new drugs against pathogenic parasites and fungi","volume":"39","author":"Ebiloma","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/acs.jmedchem.6b01740","article-title":"Conjugates of 2,4-dihydroxybenzoate and salicylhydroxamate and lipocations display potent anti-parasite effects by efficiently targeting the Trypanosoma brucei and Trypanosoma congolense mitochondrion","volume":"60","author":"Ebiloma","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/AAC.46.12.3731-3738.2002","article-title":"Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion","volume":"46","author":"Basselin","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1471-4922(03)00069-2","article-title":"Pentamidine uptake and resistance in pathogenic protozoa","volume":"19","author":"Bray","year":"2003","journal-title":"Trends Parasitol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4269\/ajtmh.1996.55.586","article-title":"The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis","volume":"55","author":"Doua","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sekhar, G.N., Georgian, A.R., Sanderson, L., Vizcay-Barrena, G., Brown, R.C., Muresan, P., Fleck, R.A., and Thomas, S.A. (2017). Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB). PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173474"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.actatropica.2004.03.010","article-title":"Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis (4-amidinophenyl) furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue","volume":"91","author":"Sturk","year":"2004","journal-title":"Acta Trop."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1124\/jpet.108.149872","article-title":"Pentamidine movement across the murine blood-brain and blood-CSF barriers; effect of trypanosome infection, combination therapy, P-glycoprotein and MRP","volume":"329","author":"Sanderson","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1128\/AAC.02605-14","article-title":"Pharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis","volume":"58","author":"Yang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Myburgh, E., Coles, J.A., Ritchie, R., Kennedy, P.G., McLatchie, A.P., Rodgers, J., Taylor, M.C., Barrett, M.P., Brewer, J.M., and Mottram, J.C. (2013). In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002384"},{"key":"ref_40","first-page":"876","article-title":"Diamidines for human African trypanosomiasis","volume":"11","author":"Paine","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pohlig, G., Bernhard, S.C., Blum, J., Burri, C., Mpanya, A., Lubaki, J.P., Mpoto, A.M., Munungu, B.F., N\u2019tombe, P.M., and Deo, G.K. (2016). Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international phase 3 clinical trial. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004363"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/AAC.00225-09","article-title":"New treatment option for second-stage African sleeping sickness: In vitro and in vivo efficacy of aza analogs of DB289","volume":"53","author":"Wenzler","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Thuita, J.K., Wolf, K.K., Murilla, G.A., Bridges, A.S., Boykin, D.W., Mutuku, J.N., Liu, Q., Jones, S.K., Gem, C.O., and Ching, S. (2015). Chemotherapy of second stage human African trypanosomiasis: Comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003409"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28153","DOI":"10.1074\/jbc.270.47.28153","article-title":"Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei","volume":"270","author":"Carter","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0001-706X(01)00177-2","article-title":"Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter","volume":"80","author":"Jarvis","year":"2001","journal-title":"Acta Trop."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/AAC.48.5.1515-1519.2004","article-title":"The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter; additional insights in diamidine resistance in African trypanosomes","volume":"48","author":"Anderson","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.285.5425.242","article-title":"A nucleoside transporter from Trypanosoma brucei involved in drug resistance","volume":"285","author":"Kralli","year":"1999","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/EC.2.5.1003-1008.2003","article-title":"The mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei","volume":"2","author":"Matovu","year":"2003","journal-title":"Eukaryot. Cell"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Graf, F.E., Ludin, P., Wenzler, T., Kaiser, M., Pyana, P., B\u00fcscher, P., De Koning, H.P., Horn, D., and M\u00e4ser, P. (2013). Aquaporin 2 mutations in Trypanosoma b. gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002475"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/mmi.12979","article-title":"Functional analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and the proposal of a structural model for the protein","volume":"96","author":"Munday","year":"2015","journal-title":"Mol. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1124\/mol.56.6.1162","article-title":"Adenosine transporters in bloodstream forms of T. b. brucei: Substrate recognition motifs and affinity for trypanocidal drugs","volume":"56","author":"Jarvis","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"34028","DOI":"10.1074\/jbc.M109.049726","article-title":"Predictive computational models of substrate binding by a nucleoside transporter","volume":"284","author":"Collar","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/mol.59.3.586","article-title":"Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters. Implications for crossresistance with arsenicals","volume":"59","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1124\/mol.106.031351","article-title":"Loss of the High Affinity Pentamidine Transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes","volume":"71","author":"Bridges","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkt442","article-title":"Trypanosoma brucei Aquaglyceroporin 2 is a high affinity transporter for pentamidine and melaminophenyl arsenic drugs and is the main genetic determinant of resistance to these drugs","volume":"69","author":"Munday","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"Alsford","year":"2012","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10996","DOI":"10.1073\/pnas.1202885109","article-title":"Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes","volume":"109","author":"Baker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Song, J., Baker, N., Rothert, M., Henke, B., Jeacock, L., Horn, D., and Beitz, E. (2016). Pentamidine is not a permeant but a nanomolar inhibitor of the Trypanosoma brucei Aquaglyceroporin-2. PLoS Pathog., 2.","DOI":"10.1371\/journal.ppat.1005436"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.111.071555","article-title":"The diamidine diminazene aceturate is a substrate for the High Affinity Pentamidine Transporter: Implications for the development of high resistance levels","volume":"80","author":"Teka","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1550-7408.1975.tb00943.x","article-title":"Protein uptake and digestion in bloodstream and culture forms of Trypanosoma brucei","volume":"22","author":"Langreth","year":"1975","journal-title":"J. Protozool."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrmicro2221","article-title":"The trypanosome flagellar pocket","volume":"7","author":"Field","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fphar.2015.00032","article-title":"Transport proteins determine drug sensitivity and resistance in a protozoan parasite, Trypanosoma brucei","volume":"6","author":"Munday","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_63","unstructured":"Alghamdi, A., Munday, J.C., Campagnaro, G., Eze, A.A., Svensson, F., Martin Abril, E., Milic, P., Dimitriou, A., Wielinska, J., and Smart, G. (2020). Pentamidine enters Trypanosoma brucei by passing through the pore of the aquaglyceroporin TbAQP2, (submitted)."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Unciti-Broceta, J.D., Arias, J.L., Maceira, J., Soriano, M., Ortiz-Gonz\u00e1lez, M., Hern\u00e1ndez-Quero, J., Mu\u00f1\u00f3z-Torres, M., De Koning, H.P., Magez, S., and Garcia-Salcedo, J.A. (2015). Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis. PloS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004942"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"(1858). Livingstone D (1858) Arsenic as a remedy for the tsetse bite. Brit. Med. J., 1, 360\u2013361.","DOI":"10.1136\/bmj.s4-1.70.360-a"},{"key":"ref_66","unstructured":"Bruce, D. (1895). Preliminary Report on the Tsetse Fly Disease or Nagana, Zululand."},{"key":"ref_67","unstructured":"Mulligan, H.W. (1970). The African Trypanosomiases, George Allen and Unwin Ltd."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1021\/ja02232a012","article-title":"Aromatic arsenic compounds v. N-substituted glycylarsanilic acids","volume":"41","author":"Jacobs","year":"1919","journal-title":"J. Am. Chem. Soc."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Dumas, M., Bouteille, B., and Buguet, A. (1999). Present strategies in the treatment of human African trypanosomiasis. Progress in Human African Trypanosomiasis, Sleeping Sickness, Springer.","DOI":"10.1007\/978-2-8178-0857-4"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0035-9203(84)90002-6","article-title":"Arsenic and old taxa: Subspeciation and drug sensitivity in Trypanosoma brucei","volume":"78","author":"Dukes","year":"1984","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_71","first-page":"499","article-title":"Sur les isom\u00e8res de l\u2019acide para-oxy-3-amino-ph\u00e9nyl-arsinique et de son d\u00e9riv\u00e9 ac\u00e9tyl\u00e9 (stovarsol)","volume":"41","author":"Fourneau","year":"1927","journal-title":"Bull. Soc. Chim. Fr."},{"key":"ref_72","unstructured":"Mulligan, H.W. (1970). Treatment of human trypanosomiasis. The African Trypanosomiases, George Allen and Unwin Ltd."},{"key":"ref_73","first-page":"830","article-title":"Essai du traitement de la trypanosomiase humaine par le 270 Fourneau","volume":"40","author":"Ledentu","year":"1926","journal-title":"Ann. Inst. Pasteur"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Laveissi\u00e8re, C., and Penchenier, L. (2005). Manuel De Lutte Contre La Maladie Du Sommeil, \u00e9ditions de l\u2019Institut de recherche pour le d\u00e9veloppement, coll. Didactiques. IRD Editions.","DOI":"10.4000\/books.irdeditions.10497"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-3156.2001.00753.x","article-title":"Trypanosomiase humaine africaine: Historique de la th\u00e9rapeutique et de ses \u00e9checs","volume":"6","author":"Ollivier","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/00034983.1949.11685405","article-title":"Studies on the chemotherapy of melaminyl arsenicals and antimonials in laboratory trypanosome infections","volume":"43","author":"Rollo","year":"1949","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0035-9203(44)90039-8","article-title":"Pentamidine is the prevention and treatment of trypanosomiasis","volume":"37","author":"Henrard","year":"1944","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/00034983.1937.11684975","article-title":"Studies in chemotherapy XIV\u2014The stability of drug-resistance in trypanosomes","volume":"31","author":"Murgatroyd","year":"1937","journal-title":"Ann. Trop. Med. Parsitol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00001432-199112000-00020","article-title":"therapy for African trypanosomiasis","volume":"4","author":"Wery","year":"1991","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_80","first-page":"386","article-title":"Contribution \u00e0 l\u2019\u00e9tude de produits a radical m\u00e9laminyl dans le traitement de la trypanosmiase humaine \u00e0 Tr gambiense","volume":"3","author":"Jonchere","year":"1953","journal-title":"Bull. Soc. Pathol. Exot."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-3156.2001.00710.x","article-title":"Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis","volume":"6","author":"Blum","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0035-9203(94)90430-8","article-title":"Gambiense trypanosomiasis: Frequency of, and risk factors for, failure of melarsoprol therapy","volume":"88","author":"Milord","year":"1994","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1086\/429929","article-title":"Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (IMPAMEL II)","volume":"191","author":"Schmid","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Rodgers, J., Jones, A., Gibaud, S., Bradley, B., McCabe, C., Barrett, M.P., Gettinby, G., and Kennedy, P.G.E. (2011). Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis. PLOS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001308"},{"key":"ref_85","unstructured":"(2020, January 17). Committee for Orphan Medicinal Products (COMP) Meeting Report on the Review of Applications for Orphan Designation. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/committee-report\/comp-meeting-report-review-applications-orphan-designation-october-2012_en.pdf."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/167147a0","article-title":"Acquired resistance to \u2018Melarsan\u2019, tryparsamidine and amidines in pathogenic trypanosomes","volume":"167","author":"Rollo","year":"1951","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","article-title":"Drug resistance in African trypanosomiasis: The melarsoprol and pentamidine story","volume":"29","author":"Baker","year":"2013","journal-title":"Trends Parasitol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pt.2008.04.006","article-title":"The ever-increasing complexities of arsenical-diamidine cross-resistance in African trypanosomes","volume":"24","year":"2008","journal-title":"Trends Parasitol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/361173a0","article-title":"Arsenical-resistant trypanosomes lack an unusual adenosine transporter","volume":"361","author":"Carter","year":"1993","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0166-6851(99)00206-6","article-title":"Further evidence for a link between melarsoprol resistance and P2 transporter function in African trypanosomes","volume":"106","author":"MacLeod","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0966-842X(99)01643-1","article-title":"A drug resistance determinant from Trypanosoma brucei","volume":"7","author":"Carter","year":"1999","journal-title":"Trends Microbiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1365-3156.2007.01918.x","article-title":"Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction","volume":"12","author":"Nerima","year":"2007","journal-title":"Trop. Med. Int. Health"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-6851(01)00332-2","article-title":"Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy","volume":"117","author":"Matovu","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2217\/fmb.11.88","article-title":"Drug resistance in human African trypanosomiasis","volume":"6","author":"Barrett","year":"2011","journal-title":"Future Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1046\/j.1365-3156.2001.00775.x","article-title":"The phenomenon of treatment failures in Human African Trypanosomiasis","volume":"6","author":"Brun","year":"2011","journal-title":"Trop. Med. Int. Health"},{"key":"ref_96","first-page":"171","article-title":"Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda","volume":"92","author":"Legros","year":"1999","journal-title":"Bull. Soc. Pathol. Exot."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1365-3156.2001.00714.x","article-title":"Re-emergence of epidemic sleeping sickness in southern Sudan","volume":"6","author":"Moore","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1406.071266","article-title":"High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo","volume":"14","author":"Robays","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-3156.2001.00725.x","article-title":"Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment","volume":"6","author":"Burri","year":"2001","journal-title":"Trop. Med. Int. Health"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kazibwe, A.J.N., Nerima, B., De Koning, H.P., M\u00e4ser, P., Barrett, M.P., and Matovu, E. (2009). Genotypic status of the TbAT1\/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from North western Uganda following melarsoprol withdrawal. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000523"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Pyana Pati, P., Van Reet, N., Mumba Ngoyi, D., Ngay Lukusa, I., Karhemere Bin Shamamba, S., and B\u00fcscher, P. (2014). Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003212"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpddr.2015.04.002","article-title":"Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates","volume":"5","author":"Graf","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1007\/s00018-016-2173-6","article-title":"Comparative genomics of drug resistance of the sleeping sickness parasite Trypanosoma brucei rhodesiense","volume":"73","author":"Graf","year":"2016","journal-title":"Cell. Mol. Life. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpddr.2013.01.004","article-title":"Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake","volume":"3","author":"Munday","year":"2013","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_105","first-page":"362","article-title":"Farben therapeutische Versuche bei Trypanosomerkrankung","volume":"14","author":"Ehrlich","year":"1904","journal-title":"Berl. Klin. Wochenschr."},{"key":"ref_106","first-page":"329","article-title":"Farbentherapeutische Versuche bei Trypanosomenerkrankung","volume":"41","author":"Ehrlich","year":"1904","journal-title":"Berl. Klin. Wochenschr."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-3305-3-15","article-title":"The development of drugs for treatment of sleeping sickness: A historical review","volume":"3","author":"Steverding","year":"2010","journal-title":"Parasit. Vectors"},{"key":"ref_108","first-page":"697","article-title":"Aus Theorie und Praxis der Chemotherapie","volume":"7","author":"Ehrlich","year":"1911","journal-title":"Folia Serol."},{"key":"ref_109","first-page":"417","article-title":"Traitement des trypanosomiases par les couleurs de benzidine. Premi\u00e8re partie\u2014\u00c9tude chemique","volume":"20","author":"Nicolle","year":"1906","journal-title":"Ann. Inst. Pasteur."},{"key":"ref_110","first-page":"513","article-title":"Traitement des trypanosomiases par les couleurs de benzidine. Second partie\u2014\u00c9tude exp\u00e9rimentale","volume":"20","author":"Mesnil","year":"1906","journal-title":"Ann. Inst. Pasteur."},{"key":"ref_111","first-page":"200","article-title":"Le r\u00f4le de Maurice Nicolle en chimioth\u00e9rapie anti-trypanosome","volume":"55","year":"1962","journal-title":"Bull. Soc. Pathol. Exotique."},{"key":"ref_112","first-page":"9","article-title":"Paul Ehrlich: A hundred years of chemotherapy 1891-1991","volume":"13","author":"Travis","year":"1991","journal-title":"Biochemist"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/pauz.200900344","article-title":"Wirkstoffe zur Behandlung der Afrikanischer Schlafkrankheit","volume":"6","author":"Schlitzer","year":"2009","journal-title":"Pharm. Unsere Zeit."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/bmj.1.3297.413","article-title":"Synthetic therapeutic agents","volume":"1","author":"Pope","year":"1924","journal-title":"Br. Med. J."},{"key":"ref_115","first-page":"675","article-title":"Sur une nouvelle s\u00e9rie de m\u00e9dicaments trypanocides","volume":"178","author":"Fourneau","year":"1924","journal-title":"Comptes Rendus des S\u00e9ances de l\u2019Acad\u00e9mie des Sciences"},{"key":"ref_116","first-page":"81","article-title":"Recherches de chimioth\u00e9rapie dans la s\u00e9rie du 205 Bayer. Ur\u00e9es des acides aminobenzoylaminonaphtal\u00e9niques","volume":"38","author":"Fourneau","year":"1924","journal-title":"Ann. Inst. Pasteur."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0163-7258(80)90035-2","article-title":"Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Eastern hemisphere","volume":"11","author":"Apted","year":"1980","journal-title":"Pharmac. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(08)60410-8","article-title":"The treatment of human African trypanosomiasis","volume":"33","author":"Milord","year":"1994","journal-title":"Adv. Parasitol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0001-706X(96)00131-3","article-title":"Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin","volume":"60","author":"Scott","year":"1996","journal-title":"Acta Trop."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1550-7408.1987.tb03216.x","article-title":"Receptor-mediated endocytosis in the blood-stream form of Trypanosoma brucei","volume":"34","author":"Coppens","year":"1987","journal-title":"J. Protozool."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0001-706X(93)90096-T","article-title":"The uptake of the trypanocidal drug Suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action","volume":"54","author":"Vansterkenburg","year":"1993","journal-title":"Acta Trop."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0166-6851(02)00096-8","article-title":"Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei","volume":"122","author":"Pal","year":"2002","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0006-2952(72)90064-0","article-title":"Comparative properties of schistosomal and filarial dihydrofolate reductase","volume":"21","author":"Jaffe","year":"1972","journal-title":"Biochem. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0305-0491(72)90138-1","article-title":"Comparative properties of trypanosomal and mammalian thymidine kinases","volume":"43","author":"Chello","year":"1972","journal-title":"Comp. Biochem. Physiol. B"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0166-6851(93)90218-M","article-title":"Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei","volume":"59","author":"Willson","year":"1993","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mib.2016.08.005","article-title":"Exploiting the Achilles\u2019 heel of membrane trafficking in trypanosomes","volume":"34","author":"Zoltner","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pt.2013.03.004","article-title":"Receptor-mediated endocytosis for drug delivery in African trypanosomes: Fulfilling Paul Ehrlich\u2019s vision of chemotherapy","volume":"29","author":"Alsford","year":"2013","journal-title":"Trends. Parasitol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0021-9258(18)48472-4","article-title":"Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites","volume":"267","author":"Poulin","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.1073\/pnas.79.19.6028","article-title":"\u03b1-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin","volume":"79","author":"Weeks","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","first-page":"945","article-title":"Development of difluoromethylornithine (DFMO) as a chemoprevention agent","volume":"5","author":"Meyskens","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrc1454","article-title":"Polyamines and cancer: Old molecules, new understanding","volume":"4","author":"Gerner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0140-6736(92)92180-N","article-title":"Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness","volume":"340","author":"Milord","year":"1992","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/0035-9203(85)90195-6","article-title":"Treatment of gambiense sleeping sickness in Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase: First field trial","volume":"79","author":"Schechter","year":"1985","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0002-9343(87)90107-0","article-title":"Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients","volume":"82","author":"Taelman","year":"1987","journal-title":"Am. J. Med."},{"key":"ref_136","first-page":"149","article-title":"Essai de traitement de la trypanosomiase a Trypanosoma brucei gambiense par l\u2019eflornithine en Republique Populaire du Congo","volume":"49","author":"Eozenou","year":"1989","journal-title":"Med. Trop."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ebikeme, C. (2014). The death and life of the resurrection drug. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002910"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90","author":"Burri","year":"2003","journal-title":"Parasitol. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/00034983.1989.11812414","article-title":"Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya","volume":"83","author":"Bales","year":"1989","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.34.6.1183","article-title":"Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense","volume":"34","author":"Bacchi","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","first-page":"190","article-title":"Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO)","volume":"46","author":"Iten","year":"1995","journal-title":"Trop. Med. Parasitol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1128\/AAC.41.9.1922","article-title":"Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to d,l-alpha-difluoromethylornithine","volume":"41","author":"Iten","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0166-6851(87)90086-7","article-title":"Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei","volume":"25","author":"Bellofatto","year":"1987","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0166-6851(87)90064-8","article-title":"A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine","volume":"22","author":"Phillips","year":"1987","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2007.02.004","article-title":"Drugs and drug resistance in African trypanosomiasis","volume":"10","author":"Delespaux","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0006-2952(86)90539-3","article-title":"Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei","volume":"35","author":"Bitonti","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Vincent, I.M., Creek, D., Watson, D.G., Kamleh, M.A., Woods, D.J., Wong, P.E., Burchmore, R.J., and Barrett, M.P. (2010). A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001204"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molbiopara.2010.09.002","article-title":"Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters","volume":"175","author":"Jutzi","year":"2011","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1017\/S0031182012000169","article-title":"Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis","volume":"139","author":"Simarro","year":"2012","journal-title":"Parasitology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-3156.2002.00933.x","article-title":"Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis","volume":"7","author":"Mpia","year":"2002","journal-title":"Trop. Med. Int. Health"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Priotto, G., Fogg, C., Balasegaram, M., Erphas, O., Louga, A., Checchi, F., Ghabri, S., and Piola, P. (2006). Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clin. Trials., 1.","DOI":"10.1371\/journal.pctr.0010039"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Checchi, F., Piola, P., Ayikoru, H., Thomas, F., Legros, D., and Priotto, G. (2007). Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: A case series. PLoS Negl. Trop. Dis., 1.","DOI":"10.1371\/journal.pntd.0000064"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/522982","article-title":"Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Congo","volume":"45","author":"Priotto","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Yun, O., Priotto, G., Tong, J., Flevaud, L., and Chappuis, F. (2010). NECT is next: Implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000720"},{"key":"ref_157","first-page":"93","article-title":"Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis","volume":"3","author":"Franco","year":"2012","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M\u00e9decins Sans Fronti\u00e8res experience in the Democratic Republic of the Congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13071-018-2634-x","article-title":"A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda","volume":"11","author":"Kansiime","year":"2018","journal-title":"Parasit. Vectors"},{"key":"ref_160","first-page":"1624","article-title":"The effect of nifurtimox on acute Chagas\u2019 infection","volume":"22","author":"Wegner","year":"1972","journal-title":"Arzneim. Forsch."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpddr.2019.11.004","article-title":"Current trends in the pharmacological management of Chagas disease","volume":"12","author":"Ribeiro","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_162","first-page":"475","article-title":"Clinical trials with \u201cnifurtimox\u201d in African trypanosomiasis","volume":"57","author":"Janssens","year":"1977","journal-title":"Ann. Soc. Belg. Med. Trop."},{"key":"ref_163","first-page":"37","article-title":"Essai de traitement au nifurtimox de la trypanosomiase humaine Africaine","volume":"64","author":"Moens","year":"1984","journal-title":"Ann. Soc. Belg. Med. Trop."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/0035-9203(89)90270-8","article-title":"An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire","volume":"83","author":"Pepin","year":"1989","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0035-9203(92)90298-Q","article-title":"High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: An open trial in central Zaire","volume":"86","author":"Milord","year":"1992","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_166","first-page":"39","article-title":"Advances in sleeping sickness therapy","volume":"72","year":"1992","journal-title":"Ann. Soc. Belg. Med. Trop."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/510534","article-title":"Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness","volume":"195","author":"Bisser","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0003-9861(79)90251-0","article-title":"generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi","volume":"197","author":"Docampo","year":"1979","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/AAC.01360-06","article-title":"Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole","volume":"51","author":"Prathalingham","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molbiopara.2010.11.010","article-title":"Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6","volume":"176","author":"Baker","year":"2011","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.00332-10","article-title":"Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis","volume":"54","author":"Sokolova","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1124\/jpet.110.172981","article-title":"The distribution of nifurtimox across the healthy and trypanosome-infected murine blood\u2013brain and blood-CSF barriers","volume":"336","author":"Jeganathan","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2011.11.053","article-title":"The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: Evidence for involvement of breast cancer resistance protein","volume":"1436","author":"Watson","year":"2012","journal-title":"Brain Res."},{"key":"ref_175","first-page":"1617","article-title":"Investigations on the pharmacokinetics of nifurtimox-35S in the rat and dog","volume":"22","author":"Duhm","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fphar.2014.00231","article-title":"How drugs get into cells: Tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion","volume":"5","author":"Kell","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.drudis.2011.05.010","article-title":"Pharmaceutical drug transport: The issues and the implications that it is essentially carrier-mediated only","volume":"16","author":"Kell","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1021\/jm050177+","article-title":"Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites","volume":"48","author":"Baliani","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.actatropica.2007.07.007","article-title":"Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate","volume":"104","author":"Maina","year":"2007","journal-title":"Acta Trop."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Pelfrene, E., Harvey Allchurch, M., Ntamabyaliro, N., Nambasa, V., Ventura, F.V., Nagercoil, N., and Cavaleri, M. (2019). The European Medicines Agency\u2019s scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007381"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0140-6736(18)30019-9","article-title":"Oral fexinidazole for human African trypanosomiasis","volume":"391","author":"Chappuis","year":"2018","journal-title":"Lancet"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Lindner, A.K., Lejon, V., Chappuis, F., Seixas, J., Kazumba, L., Barrett, M.P., Mwamba, E., Erphas, O., Akl, E.A., and Villanueva, G. (2019). New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: Substantial changes for clinical practice. Lancet Infect. Dis.","DOI":"10.1016\/S1473-3099(19)30612-7"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1042\/ETLS20170113","article-title":"Drug resistance in protozoan parasites","volume":"1","year":"2017","journal-title":"Emerg. Top. Life Sci."},{"key":"ref_186","first-page":"51","article-title":"Treatment of late stage sleeping sickness caused by T. b. gambiense: A new approach to the use of an old drug","volume":"132","author":"Blum","year":"2002","journal-title":"Swiss. Med. Wkly."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/5\/1\/14\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:05:24Z","timestamp":1760364324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/5\/1\/14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,19]]},"references-count":186,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["tropicalmed5010014"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed5010014","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,19]]}}}